OCUL Stock Overview
A biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ocular Therapeutix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.77 |
| 52 Week High | US$11.78 |
| 52 Week Low | US$2.89 |
| Beta | 1.26 |
| 11 Month Change | -5.97% |
| 3 Month Change | 17.01% |
| 1 Year Change | 190.77% |
| 33 Year Change | 58.09% |
| 5 Year Change | 141.83% |
| Change since IPO | -25.70% |
Recent News & Updates
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Oct 11Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Recent updates
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Oct 16Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Oct 11Earnings Update: Ocular Therapeutix, Inc. (NASDAQ:OCUL) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 10Ocular Therapeutix: A Speculative Investment For Risk-Tolerant Investors
Jul 23Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 41% But Its P/S Still Looks Reasonable
Jul 15Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Could Be 45% Below Their Intrinsic Value Estimate
Jun 05Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
Jun 01Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Shareholder Returns
| OCUL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.5% | 1.9% | 0.7% |
| 1Y | 190.8% | 12.1% | 32.2% |
Return vs Industry: OCUL exceeded the US Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: OCUL exceeded the US Market which returned 31.9% over the past year.
Price Volatility
| OCUL volatility | |
|---|---|
| OCUL Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OCUL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OCUL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 267 | Pravin Dugel | www.ocutx.com |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
Ocular Therapeutix, Inc. Fundamentals Summary
| OCUL fundamental statistics | |
|---|---|
| Market cap | US$1.55b |
| Earnings (TTM) | -US$174.34m |
| Revenue (TTM) | US$61.44m |
25.0x
P/S Ratio-8.8x
P/E RatioIs OCUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCUL income statement (TTM) | |
|---|---|
| Revenue | US$61.44m |
| Cost of Revenue | US$108.62m |
| Gross Profit | -US$47.18m |
| Other Expenses | US$127.16m |
| Earnings | -US$174.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | -76.79% |
| Net Profit Margin | -283.74% |
| Debt/Equity Ratio | 19.3% |
How did OCUL perform over the long term?
See historical performance and comparison